drugset / Trial / NCT00523640
A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma
Phase 2
Terminated
30 enrolled
University of Chicago
Eli Lilly and Company · collabGenentech, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effects (good and bad) the combination of the chemotherapy drugs gemcitabine, capecitabine, and bevacizumab has on a patient and kidney cancer.
Timeline
- Start
- 2005-03
- Primary completion
- 2011-04
- Completion
- 2011-04
Outcome
Outcome not reported
Stopped (Enrollment): “Too slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |
| Subject | Capecitabine | Small molecule | 1000 mg | Oral |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |